Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05199272 · ClinicalTrials.gov registry record · Phase 1

A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies

A Phase 1 study of Solid Tumor and Fallopian Tube Cancer, sponsored by 23andMe.

Active
Registry status
Phase 1
Development phase
141
Enrollment target
13
Study locations

NCT05199272 is a Phase 1 study of Solid Tumor and Fallopian Tube Cancer that is active but no longer recruiting, run by 23andMe. The registered enrollment target is 141 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (36% lower). The trial reports 13 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05199272, a Phase 1 study of Solid Tumor and Fallopian Tube Cancer, is active but no longer recruiting, sponsored by 23andMe.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
141 participants
Enrollment target
13
Study locations

Study Summary

This is a first-in-human open-label Phase 1/2a study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of 23ME-00610 given by intravenous infusion in patients with advanced solid malignancies who have progressed on all available standard therapies

Conditions Studied

Solid Tumor Fallopian Tube Cancer Neuroendocrine Tumors Clear Cell Renal Cell Carcinoma Epithelial Ovarian Cancer Extensive-stage Small-cell Lung Cancer Primary Peritoneal Carcinoma MSI-H Cancer Cancer With A High Tumor Mutational Burden

Interventions

  • DRUG 23ME-00610

Study Locations (13)

Ontario

  • Ottawa Hospital Cancer Centre - Ottawa
  • Princess Margaret Cancer Centre - Toronto
  • The Hospital for Sick Children - Toronto

New York

  • R.J.Zuckerberg Cancer Center - Lake Success
  • Cohen Children's Medical Center - New Hyde Park

Texas

  • MD Anderson Cancer Center - Houston
  • START Center for Cancer Care - San Antonio

California

  • Stanford Cancer Institute - Palo Alto

Georgia

  • Emory University - Atlanta

Michigan

  • Karmanos Cancer Institute - Detroit

Oregon

  • Oregon Health & Science University - Portland

Tennessee

  • Vanderbilt University - Nashville

Trial Details

FieldValue
Enrollment Target 141 participants
Start Date 2021-12-29
Est. Completion 2025-03
Phase Phase 1

Sponsor

23andMe

6 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05199272

The ClinicalTrials.gov registry entry for NCT05199272 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 141 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (36% lower). The listed sponsor is 23andMe, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 9 conditions, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which 23ME-00610 is the first listed.

NCT05199272 reports 13 study locations spanning 9 distinct geographic areas - top geographies include Ontario, New York, Texas.

Frequently Asked Questions

What is clinical trial NCT05199272 about?

NCT05199272 is a clinical study titled "A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies". This is a first-in-human open-label Phase 1/2a study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of 23ME-00610 given by intravenous infusion in patients with advanced solid malignancies who have progressed on all available standard ther...

What is the current status of trial NCT05199272?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 141 participants. The study started on 2021-12-29. Estimated completion is 2025-03.

What conditions does trial NCT05199272 study?

This clinical trial studies the following conditions: Solid Tumor, Fallopian Tube Cancer, Neuroendocrine Tumors, Clear Cell Renal Cell Carcinoma, Epithelial Ovarian Cancer.

What interventions are being tested in trial NCT05199272?

The interventions under investigation include: 23ME-00610 (DRUG).

Who is sponsoring clinical trial NCT05199272?

This trial is sponsored by 23andMe, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05199272 being conducted?

This trial has 13 study locations across California, Georgia, Michigan, New York, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Solid Tumor

All registered trials for this condition

Fallopian Tube Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.